Incorporation of non-natural amino acids improves cell permeability and potency of specific inhibitors of proteasome trypsin-like sites.

Proteasomes degrade the majority of proteins in mammalian cells by a concerted action of three distinct pairs of active sites. The chymotrypsin-like sites are targets of antimyeloma agents bortezomib and carfilzomib. Inhibitors of the trypsin-like site sensitize multiple myeloma cells to these agents. Here we describe systematic effort to develop inhibitors with improved potency and cell permeability, yielding azido-Phe-Leu-Leu-4-aminomethyl-Phe-methyl vinyl sulfone (4a, LU-102), and a fluorescent activity-based probe for this site. X-ray structures of 4a and related inhibitors complexed with yeast proteasomes revealed the structural basis for specificity. Nontoxic to myeloma cells when used as a single agent, 4a sensitized them to bortezomib and carfilzomib. This sensitizing effect was much stronger than the synergistic effects of histone acetylase inhibitors or additive effects of doxorubicin and dexamethasone, raising the possibility that combinations of inhibitors of the trypsin-like site with bortezomib or carfilzomib would have stronger antineoplastic activity than combinations currently used clinically.

[1]  Ricarda Schwab,et al.  Immuno- and Constitutive Proteasome Crystal Structures Reveal Differences in Substrate and Inhibitor Specificity , 2012, Cell.

[2]  D. Filippov,et al.  Specific cell-permeable inhibitor of proteasome trypsin-like sites selectively sensitizes myeloma cells to bortezomib and carfilzomib. , 2011, Chemistry & biology.

[3]  H. Overkleeft,et al.  Nature of Pharmacophore Influences Active Site Specificity of Proteasome Inhibitors* , 2010, The Journal of Biological Chemistry.

[4]  H. Overkleeft,et al.  Activity-based profiling reveals reactivity of the murine thymoproteasome-specific subunit beta5t. , 2010, Chemistry & biology.

[5]  H. Overkleeft,et al.  A panel of subunit-selective activity-based proteasome probes. , 2010, Organic & biomolecular chemistry.

[6]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[7]  H. Overkleeft,et al.  Incorporation of fluorinated phenylalanine generates highly specific inhibitor of proteasome's chymotrypsin-like sites. , 2010, Journal of medicinal chemistry.

[8]  M. Rolfe,et al.  Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer. , 2010, Cancer research.

[9]  Matthew Britton,et al.  Selective inhibitor of proteasome's caspase-like sites sensitizes cells to specific inhibition of chymotrypsin-like sites. , 2009, Chemistry & biology.

[10]  Evan Bolton,et al.  The PubChem chemical structure sketcher , 2009, J. Cheminformatics.

[11]  R. Orlowski,et al.  A Phase 1 Dose Escalation Study of the Safety and Pharmacokinetics of the Novel Proteasome Inhibitor Carfilzomib (PR-171) in Patients with Hematologic Malignancies , 2009, Clinical Cancer Research.

[12]  S. Demo,et al.  Design and synthesis of an orally bioavailable and selective peptide epoxyketone proteasome inhibitor (PR-047). , 2009, Journal of medicinal chemistry.

[13]  Robert D. Clark,et al.  SYBYL Line Notation (SLN): A Single Notation To Represent Chemical Structures, Queries, Reactions, and Virtual Libraries , 2008, J. Chem. Inf. Model..

[14]  H. Ovaa,et al.  CEP-18770: A novel, orally active proteasome inhibitor with a tumor-selective pharmacologic profile competitive with bortezomib. , 2008, Blood.

[15]  D. Filippov,et al.  Acetylene functionalized BODIPY dyes and their application in the synthesis of activity based proteasome probes. , 2007, Bioorganic & medicinal chemistry letters.

[16]  S. Demo,et al.  Antitumor activity of PR-171, a novel irreversible inhibitor of the proteasome. , 2007, Cancer research.

[17]  D. Filippov,et al.  A fluorescent broad-spectrum proteasome inhibitor for labeling proteasomes in vitro and in vivo. , 2006, Chemistry & biology.

[18]  Bonnie F. Sloane,et al.  Cysteine cathepsins: multifunctional enzymes in cancer , 2006, Nature Reviews Cancer.

[19]  A. Goldberg,et al.  Importance of the Different Proteolytic Sites of the Proteasome and the Efficacy of Inhibitors Varies with the Protein Substrate* , 2006, Journal of Biological Chemistry.

[20]  Hiroshi Yasui,et al.  A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib. , 2005, Cancer cell.

[21]  K. Anderson,et al.  Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells. , 2005, Cancer research.

[22]  K. Anderson,et al.  Activity probe for in vivo profiling of the specificity of proteasome inhibitor bortezomib , 2005, Nature Methods.

[23]  Fei Long,et al.  REFMAC5 dictionary: organization of prior chemical knowledge and guidelines for its use. , 2004, Acta crystallographica. Section D, Biological crystallography.

[24]  J. Adams.  The development of proteasome inhibitors as anticancer drugs. , 2004, Cancer cell.

[25]  K. Anderson,et al.  The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. , 2003, Blood.

[26]  R. Huber,et al.  Probing structural determinants distal to the site of hydrolysis that control substrate specificity of the 20S proteasome. , 2002, Chemistry & biology.

[27]  T. Mizushima,et al.  The structure of the mammalian 20S proteasome at 2.75 A resolution. , 2002, Structure.

[28]  W. Delano.  Unraveling hot spots in binding interfaces: progress and challenges. , 2002, Current opinion in structural biology.

[29]  A. Goldberg,et al.  The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. , 2001, Molecular cell.

[30]  P. Elliott,et al.  The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. , 2001, Cancer research.

[31]  M. Bogyo,et al.  Global analysis of proteasomal substrate specificity using positional-scanning libraries of covalent inhibitors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[32]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[33]  R. Huber,et al.  Structure of 20S proteasome from yeast at 2.4Å resolution , 1997, Nature.

[34]  R M Esnouf,et al.  An extensively modified version of MolScript that includes greatly enhanced coloring capabilities. , 1997, Journal of molecular graphics & modelling.

[35]  W. Vale,et al.  Gonadotropin-releasing hormone antagonists: novel members of the azaline B family. , 1995, Journal of medicinal chemistry.

[36]  R. Huber,et al.  Crystal structure of the 20S proteasome from the archaeon T. acidophilum at 3.4 A resolution. , 1995, Science.

[37]  Wolfgang Kabsch,et al.  Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants , 1993 .

[38]  W. F. Hoffman,et al.  A simple and inexpensive synthesis of 4-(aminomethyl)-L-phenylalanine , 1993 .

[39]  S J Wodak,et al.  SFCHECK: a unified set of procedures for evaluating the quality of macromolecular structure-factor data and their agreement with the atomic model. , 1999, Acta crystallographica. Section D, Biological crystallography.

[40]  H. Kirschke,et al.  Cathepsin S and related lysosomal endopeptidases. , 1994, Methods in enzymology.

[41]  H. Kirschke,et al.  [34] Cathepsin S and related lysosomal endopeptidases , 1994 .

[42]  A. Brünger.  Free R value: a novel statistical quantity for assessing the accuracy of crystal structures , 1992, Nature.